National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships Rev. 10/21/2014 APGO Interaction with Industry: A Medical.

Slides:



Advertisements
Similar presentations
Professional Education Support Wyeth Pharmaceuticals Melinda Somasekhar, PhD.
Advertisements

CME 101 The Application Process Sponsored by the Office of Continuing Medical Education.
Continuing Professional Development Conflict of Interest This presentation has been developed by the COI Working Group to assist in the implementation.
Conflict of Interest in Physician-Industry Relationships
Managing Conflicts of Interest © ACCME.
 Why are you reading this? Both the Public Health Service and the National Science Foundation require WSU to provide all investigators training related.
Personal financial benefit or economic interest from one’s position that may inappropriately: influence the employee’s judgment compromise the employee’s.
O PEN P AYMENTS An Explanation of Section 6002 of the Affordable Care Act Center for Program Integrity September, 2013 CMS Disclaimer: This information.
Accreditation Canada & ISMP Canada ISMP Community of Practice Medication Reconciliation October 15, 2008.
1 UCDHS Vendor Relations Policy Development & Implementation Teresa Porter, CHC - Chief Compliance Officer David Levine, JD - Legal Counsel Allan Siefkin,
Conflict of Interest. Definition  “A conflict of interest is a situation in which financial or other personal considerations have the potential to compromise.
Dr. Dalal AL-Matrouk KBA Farwaniya Hospital
Promoting Objectivity in Research by Managing, Reducing, or Eliminating Conflicts of Interest UT HOP UT HOP The University of Texas at Austin.
Clinical Pharmacy Basma Y. Kentab MSc..
Presented By Sheila Lucas Ferris State University NURS 511
By: Fiona Lane. History The AHA was founded in 1898 The AHA provides education for health care leaders and is a source of information on health care issues.
# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.
Critical Role of ICT in Parliament Fulfill legislative, oversight, and representative responsibilities Achieve the goals of transparency, openness, accessibility,
Open Payments Act AKA the ‘Sunshine Act’ Open Payments Act AKA the ‘Sunshine Act’ Public Postings of Physician Ownership, Investments, & Transfers of Value.
Role of Industry in Clinical Care, Research and Education Rev 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.
VCU School of Medicine Policy on Industry Relations Effective July 1, 2009.
ENGAGING LEADERS FOR CHANGE AND INNOVATION ADEA CCI 2011 Summer Liaison Meeting San Diego, CA June 27-29, 2011 Janet M. Guthmiller, DDS, PhD University.
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
Compliance Issues for Medical Research at Healthcare Systems Jerry Castellano, Pharm.D., CIP Corporate Director Institutional Review Board Christiana Care.
Institutional Evaluation of medical faculties Prof. A. Сheminat Arkhangelsk 2012.
Pitfalls and Lessons Learned: Advanced Implementation Strategies for a Compliant Grant Process National CME Audioconference December 9, 2008.
Research Conflicts of Interest: Identifying and Minimizing COI from the Perspective of Faculty July 30, 2009 PonJola Coney, MD Senior Associate Dean for.
Transparency in Grants and Gifts Pfizer Approach Cathryn Clary, MD VP, US External Medical Affairs.
+ Conflict of Interest in Physician-Industry Relationships.
© 2011 Partners Harvard Medical International Strategic Plan for Teaching, Learning and Assessment Program Teaching, Learning, and Assessment Center Strategic.
Vendor Relations Policy. Why Is There A Policy? The Patient Protection and Affordable Care Act was signed into law March 23, The new law contains.
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
A Focus on CME and Grants Nancy Coddington, PhD Senior Director, Compliance Operations AstraZeneca Pharmaceuticals LP And Terry Hisey Deputy Managing Principal.
D.Zucker Draft-EB09 Ethics & Academic Technology Transfer: Patients, Products and Public Trust Deborah Zucker, MD, PhD, Tufts Medical Center.
Disclosure of Financial Conflicts of Interest in Continuing Medical Education Michael D. Jibson, MD, PhD and Jennifer Seibert, MD University of Michigan.
Program Co-Development in CME: Where have we been? Where are we going? Workshop Facilitators: Dr. Craig Campbell Dr. Jamie Meuser September 21,
+ Role of Industry in Clinical Care, Research, and Education.
EFPIA and IFPMA Code Compliance Strategies Richard BERGSTRÖM Chair, EFPIA Code Steering Committee Chair, IFPMA Code Compliance Network Presentation at.
Partners Conflict of Interest Policy and Reporting October 11, 2012.
1 Harvard University Cambridge, MA March 29, 2007 Medical Device Congress AdvaMed’s Efforts to Promote Compliance Christopher L. White, Esq. Executive.
Copyright © Harvard Medical School. All Rights Reserved. Outside Activity Report: What Do I Need to Report?
Sara Lovell, CPCS Education Coordinator Providence Alaska Medical Center.
Shelly Rose Ziegler. Overview Gifts from Industry Industry Site Access Academic Activities Questions  Growing external perception that industry has influence.
ROPES & GRAY LLP The Compliance Environment and Grant Process: Oversight and Response in the Pharmaceutical Industry Howard L. Dorfman December 9, 2008.
ACCME at the International Pharmaceutical Compliance Summit Philadelphia March 2005.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
Lilly Answers that Matter. Preserving the Value of Industry Interactions with Health Care Professionals Jack Harris, M.D. Vice President, U.S. Medical.
Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.
FDA Regulatory and Compliance Symposium Industry Collaboration & Interactions with Health Professionals: Can Conflicts of Interest be Properly Managed?
H ⊕ lger Schünemann, MD, PhD Professor and Chair, Dept. of Clinical Epidemiology & Biostatistics Professor of Medicine Michael Gent Chair in Healthcare.
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
 Pharmaceutical Care is a patient-centered, outcomes oriented pharmacy practice that requires the pharmacist to work in concert with the patient and.
0 Case Study #1 Global Ophthalmology. ACADEMY OF OPHTHALMOLOGY Disclosure  The speaker has no financial interest in the subject matter.
CME Process and Accreditation Criteria Objectives Explain Updated ACCME Accreditation Criteria Utilize the revised CME Planning Process to incorporate.
Disclosure of Financial Interest Policy. Medical Staff Policy Approved by the MEC’s Aimed at protecting the integrity of the LMHS Medical Staffs Requires.
Disclosure UK Talking about Transparency.
Disclosure UK Talking about Transparency.
CME and Consultants Compliance Roundtable
An Introduction to the Sunshine Act
AGREEMENT FOR TRANSPARENCY The Case of Mexico
CanMEDS Roles Covered X
Industry Induction Course
CanMEDS Roles Covered X
Updates to the PhRMA Code on Interactions with Healthcare Professionals National Pharma Audioconference August 5, 2008.
SAMPLE ONLY Dominion Health Center: Excellence in Medicaid Managed Care (or another defining message) Dominion Health Center is a community health center.
SAMPLE ONLY Dominion Health Center: Your Community Partner for Excellent Care (or another defining message) Dominion Health Center is a community health.
SAMPLE ONLY Dominion Health Center: Your Community Healthcare Home (or another defining message) Dominion Health Center is a community health center.
SAMPLE ONLY Dominion Health Center: Your Community Partner for Excellent Care (or another defining message) Dominion Health Center is a community health.
CanMEDS Roles Covered X
Presentation transcript:

National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide

Objectives List the agencies that regulate industry and identify relationships that are of importance in our field Describe the common features of conflict of interest guidelines regarding physicians’relationships with the pharmaceutical industry Summarize your own institutional guidelines Become familiar with the websites where you can go for more information on physician relationships with industry

Guidelines on Physician Interaction with Industry In recent years, there has been an increase in regulatory guidelines in the area of conflict of interest with a focus on physician relationships with the pharmaceutical industry Reasons for this increase include: – Potential influence of pharmaceutical marketing on patient care – Bias in research and results reporting – Rising costs of health care – Fraud and abuse

Guidelines on Physician Interaction with Industry American Medical Association (AMA) Association of American Medical College (AAMC) Accreditation Council for Continuing Medical Education (ACCME) American College of Obstetricians and Gynecologists (ACOG) Association of Professors of Obstetrics and Gynecology (APGO) Pharmaceutical Research and Manufacturers of America (PhRMA) Advanced Medical Technology Association (AdvaMed Code) Physician Payments Sunshine Act (CMS)

AMA (hyperlinks will be active in presentation mode) The American Medical Association (AMA) has an extensive code of ethics. It includes several sections concerning conflicts of interest: Opinion Gifts to Physicians from Industry Opinion Opinion Financial Relationships with Industry in CME Opinion Opinion COI in Biomedical Research Opinion Opinion Managing Conflicts of Interest in Clinical Trials Opinion

AAMC (hyperlinks will be active in presentation mode) Offers a number of resources for members regarding conflicts of interestnumber of resources Conflicts of Interest in Research AAMC Report on Institutional Approaches to Implementing the Final NIH Rule on Financial Conflicts of Interest (2012) AAMC Report on Institutional Approaches to Implementing the Final NIH Rule on Financial Conflicts of Interest Conflicts of Interest in Medical Education Report of the AAMC Task Force on Industry Funding of Medical Education (2008) Report of the AAMC Task Force on Industry Funding of Medical Education Reviewed on next slide Conflicts of Interest in Clinical Care In the Interest of Patients” Recommendations for Physician Financial Relationships and Clinical Decision Making (2010) In the Interest of Patients” Recommendations for Physician Financial Relationships and Clinical Decision Making Science Behind Conflicts of Interest AAMC Symposium on the Scientific Basis of Influence and Reciprocity (2007) AAMC Symposium on the Scientific Basis of Influence and Reciprocity

AAMC (cont’d) (hyperlink will be active in presentation mode) Goal of the task force report, Industry Funding of Medical Education (June 2008), was to examine the benefits/pitfalls associated with industry funding of medical education and offer principles, recommendations, and guidelines to assist in refashioning industry relationships to better conform to high standards of medical professionalismIndustry Funding of Medical Education Recommendations – Academic medical centers should establish a central CME office where support and funds for CME activity are coordinated and overseen – Pharmaceutical samples (if permitted) should be centrally managed with vouchers for low- income patients. – Site access by pharmaceutical representatives restricted to non-patient care areas and by appointment only – Site access by devise manufacturers in patient care requires appointments, credentialing, and disclosure and consent by patients – Exclude professionals with financial relationships with drug manufacturers from Pharmacy and Therapeutic Committees and the FDA Advisory Committees. – Faculty should not serve as members of speakers’ bureaus.

ACCME (hyperlink will be active in presentation mode) The ACCME Standards for Commercial Support describes practices considered appropriate for accredited providers to ensure CME activities are independent, free of commercial bias and beyond the control of persons or organizations with an economic interest in influencing the content of CMEACCME Standards for Commercial Support Six standards are enumerated, each with subsections Standard 1: Independence Standard 2: Resolution of Personal Conflicts of Interest Standard 3: Appropriate Use of Commercial Support Standard 4: Appropriate Management of Associated Commercial Promotion Standard 5: Content and Format without Commercial Bias Standard 6: Disclosures Relevant to Potential Commercial Bias

ACOG (hyperlink will be active in presentation mode) Professional Relationships with Industry (November 2012) Professional Relationships with Industry Comprehensive recommendations for practicing physicians on structuring relationships that will enhance, rather than detract from, their obligations to their patients in the following areas: Product promotion to individual physicians by advertising, personal communication, and provision of samples Support of educational activities for individual physicians Industry-sponsored device training Industry sponsorship of research Importance of physicians acting as consultants to industry

APGO (hyperlink will be active in presentation mode) Policy on Ob-Gyn Educators’ Interaction with Industry Policy on Ob-Gyn Educators’ Interaction with Industry (March 2012) APGO promotes the responsible education of teachers and leaders in women’s health care with respect to their interactions with industry. APGO recognizes that continuing instruction is paramount in appropriate and ethical interactions during and after training as part of life-long learning. APGO is dedicated to providing the tools and materials necessary to connect educators with the most current innovations in medicine and industry, as well as updates to regulatory guidelines.

APGO (cont’d) (hyperlink will be active in presentation mode) APGO recognizes that some advancements in medical and surgical care originate from collaborations with industry. APGO is committed to fostering responsible relationships with our industry partners so that medical educators can become proficient in teaching the skills necessary to allow learners to safely and effectively employ innovations in medical therapy. An artificial and ambiguous divide exists when interaction is forbidden, which then prevents and/or prohibits bringing important and improved technologies and treatments to our patients. Adaptation and integration of these improvements may be further delayed because of barriers in access to the leaders and teachers who should disseminate skills and information. APGO support policies and forums that foster a fair and unbiased exchange of information. APGO has adopted guidelines for appropriate disclosure of all conflicts of interest.guidelines

PhRMA (hyperlink will be active in presentation mode) Guidelines on Physicians’ Interactions with Industry “Ethical relationships with health care professionals are critical to our mission” The Pharmaceutical Research and Manufacturers of America (PhRMA) represents research-based pharmaceutical and biotechnology companies which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA members alone invested an estimated $50.3 billion in 2008 in discovering and developing new medicines. Industry-wide research and investment reached a record $65.2 billion in Developed and published “Code on Interactions with Health Care Professionals” which took effect Jan 2009.

PhRMA Guidelines on Physician Interactions with Industry (hyperlink will be active in presentation mode) “Ethical relationships with healthcare professionals are critical to our mission of helping patients by developing and marketing new medicines. An important part of achieving this mission is ensuring that healthcare professionals have the latest, most accurate information available regarding prescription medicines, which play an ever-increasing role in patient healthcare. This document focuses on our interactions with healthcare professionals that relate to the marketing of our products.” professionals professionals

AdvaMed (hyperlink will be active in presentation mode) AdvaMed Code of Ethics on Interactions with Health Care Professionals (AdvaMed Code) (2009) facilitates ethical interactions between MedTech companies and healthcare professionals to ensure that medical decisions are based on the best interests of the patient. AdvaMed Code of Ethics on Interactions with Health Care Professionals It clarifies and distinguishes appropriate activity between health care professionals and representatives of AdvaMed member companies.

Physician Payment Sunshine Act (hyperlink will be active in presentation mode) Physician Payments Sunshine ActPhysician Payments Sunshine Act - Center for Medicare & Medicaid Services (CMS) (2013) This program is a national resource for beneficiaries, consumers, and providers to better understand relationships between physicians, teaching hospitals, and industry. Collaboration among physicians, teaching hospitals, and industry manufacturers can contribute to the design and delivery of life-saving drugs and devices. However, while some collaboration is beneficial, payments from manufacturers to physicians and teaching hospitals can also introduce conflicts of interest. Open Payments is a national disclosure program that promotes transparency by publishing the financial relationships between the medical industry and healthcare providers (physicians and hospitals) on a publicly accessible website developed by CMS. Physicians have the right to review their reports and challenge reports that are false, inaccurate or misleading

Physician Payment Sunshine Act (cont’d) (hyperlinks will be active in presentation mode) The program requires that the following information is reported annually to CMS: Applicable manufacturers of covered drugs, devices, biologicals, and medical supplies to report payments or other transfers of value they make to physicians and teaching hospitals to CMS. Applicable manufacturersphysiciansteaching hospitals Applicable manufacturers and applicable group purchasing organizations (GPOs) to report to CMS certain ownership or investment interests held by physicians or their immediate family members.applicable group purchasing organizations (GPOs) Applicable GPOs to report to CMS payments or other transfers of value made to physician owners or investors if they held ownership or an investment interest at any point during the reporting year.

Do you know your own institutional guidelines?

AMSA Scorecard (hyperlink will be active in presentation mode) AMSA Scorecard: Conflict of Interest Policies at Academic Medical Centers The Scorecard is an institution-specific evolving tool that uses letter grades to assess schools’ performance in fourteen potential areas of conflict of interest. It offers a comprehensive look at the changing landscape of conflict- of-interest policies across US medical education, as well as in-depth assessments of individual policies that govern industry interaction between students, faculty, and the pharmaceutical and medical device industries.

Know your responsibilities for reporting potential or actual conflicts of interest.

Understand how to manage relationships with potential conflicts at your institution. Avoiding those relationships is not the answer.

“The key to success is collaboration. Industry cannot do this alone, physicians cannot do this alone, medical and communications companies can’t do this alone.” Mike Saxton Director of Clinical Education, Pharmacia